Loading...
XLONHIK
Market cap5.53bUSD
Dec 23, Last price  
1,988.00GBP
1D
1.79%
1Q
6.82%
Jan 2017
5.02%
IPO
604.96%
Name

Hikma Pharmaceuticals PLC

Chart & Performance

D1W1MN
XLON:HIK chart
P/E
2,910.26
P/S
192.33
EPS
0.86
Div Yield, %
0.03%
Shrs. gr., 5y
-1.68%
Rev. gr., 5y
6.79%
Revenues
2.88b
+14.22%
212,377,000262,215,000317,022,000448,796,000580,656,000636,884,000730,936,000918,025,0001,108,721,0001,365,000,0001,489,000,0001,440,000,0001,950,000,0001,936,000,0002,070,000,0002,207,000,0002,341,000,0002,553,000,0002,517,000,0002,875,000,000
Net income
190m
+1.06%
37,458,00043,867,00054,522,00062,576,00057,125,00077,683,00098,849,00080,107,000100,320,000212,000,000278,000,000252,000,000155,000,000-843,000,000282,000,000486,000,000431,000,000421,000,000188,000,000190,000,000
CFO
608m
+14.72%
32,842,00032,713,00029,992,00043,117,00057,872,000105,518,000138,786,000102,639,000182,161,000337,000,000425,000,000366,000,000293,000,000443,000,000430,000,000472,000,000464,000,000638,000,000530,000,000608,000,000
Dividend
Aug 15, 202424.73536 GBP/sh
Earnings
Feb 20, 2025

Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
URL
https://www.hikma.com/
IPO date
Nov 01, 2005
Employees
8,700
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,875,000
14.22%
2,517,000
-1.41%
2,553,000
9.06%
Cost of revenue
2,249,000
1,905,000
1,883,000
Unusual Expense (Income)
NOPBT
626,000
612,000
670,000
NOPBT Margin
21.77%
24.31%
26.24%
Operating Taxes
89,000
42,000
124,000
Tax Rate
14.22%
6.86%
18.51%
NOPAT
537,000
570,000
546,000
Net income
190,000
1.06%
188,000
-55.34%
421,000
-2.32%
Dividends
(137,000)
(125,000)
(120,000)
Dividend yield
3.44%
3.58%
2.32%
Proceeds from repurchase of equity
971,000
BB yield
-27.81%
Debt
Debt current
161,000
148,000
121,000
Long-term debt
1,096,000
1,144,000
734,000
Deferred revenue
1,055,000
627,000
Other long-term liabilities
102,000
(1,074,000)
(651,000)
Net debt
963,000
948,000
359,000
Cash flow
Cash from operating activities
608,000
530,000
638,000
CAPEX
(169,000)
(138,000)
(145,000)
Cash from investing activities
(333,000)
(607,000)
(238,000)
Cash from financing activities
(337,000)
(58,000)
(287,000)
FCF
510,000
608,000
434,000
Balance
Cash
229,000
292,000
450,000
Long term investments
65,000
52,000
46,000
Excess cash
150,250
218,150
368,350
Stockholders' equity
2,209,000
2,145,000
2,245,000
Invested Capital
3,351,750
3,231,850
3,027,650
ROIC
16.31%
18.21%
18.40%
ROCE
17.88%
17.64%
19.59%
EV
Common stock shares outstanding
222,369
225,000
233,000
Price
17.89
15.27%
15.52
-30.06%
22.19
-11.87%
Market cap
3,978,176
13.92%
3,492,000
-32.46%
5,170,270
-13.73%
EV
4,952,176
4,732,000
5,603,270
EBITDA
816,000
794,000
839,000
EV/EBITDA
6.07
5.96
6.68
Interest
90,000
77,000
56,000
Interest/NOPBT
14.38%
12.58%
8.36%